Introduction
The survival of patients with multiple myeloma (MM) has improved significantly over the past two decades. 1 High-dose chemotherapy with autologous hematopoietic cell transplantation (HCT) improves survival compared with conventional chemotherapy or novel agents. 2, 3 However, despite high remission and survival rates, the risk of progressive disease remains a concern after both single and tandem HCT. 4 Allogeneic HCT, which provides a tumor-free graft, has been considered as an alternative treatment with curative potential for patients with myeloma. The potential long term benefit is attributed to the graft-versus-myeloma (GVM) effect, best demonstrated by higher molecular remissions after donor lymphocyte infusions. 5 Early studies evaluating allogeneic HCT with myeloablative conditioning regimens demonstrated improved molecular remissions and lower rates of relapse, but were hindered by high treatment-related mortality. 6 More recently, the combination of autologous transplant followed by reduced intensity allogeneic transplant appears to retain the potent GVM effect while reducing treatment-related mortality (TRM). 7 To date, five large prospective trials [8] [9] [10] [11] [12] [13] involving approximately 1600 patients have shown a lack of overall survival (OS) advantage with the auto/allo HCT approach, while two trials [14] [15] [16] involving approximately 500 patients have demonstrated a survival benefit. Differences in outcome can be attributed to differences in study design, including the target population, conditioning regimen, sibling donor availability, and length of follow up ( Supplemental Table 1 ). Two published meta-analysis also did not show an OS benefit for auto/allo over auto/auto HCT. 17, 18 In the largest trial by Krishnan et al, 12 outcomes of 710 MM patients receiving auto/allo HCT (226 patients, low dose total body irradiation conditioning for allo HCT) vs. tandem auto HCT (484 patients) by biological assignment (based on availability of human leukocyte antigen (HLA)-matched sibling donor) were compared. There was no significant difference in 3-year progression free survival (PFS)/OS between auto/allo HCT and tandem auto-HCT group (PFS: 43% vs. 46%, p= 0.671 and OS: 77% vs. 80%, p=0.191) . A criticism of the study was the follow up time of 36 months, which was thought to be too short to reveal the possible favorable effects of an allo HCT. One of the unanswered questions of this trial as well as other auto/allo HCT trials is not only comparisons of PFS with tandem auto-HCT vs auto/allo HCT with longer followup, but also the long term impact of these treatment modalities. Since these trials used transplant in the upfront setting, patients had many treatment choices at the time of relapse.
Most of the trials above measured OS from the time of transplant and there have been reports of OS for MM in CIBMTR population after alloHCT 20, 29 . Gahrton, et al. have demonstrated that survival after relapse was superior in the auto/allo recipients compared with auto/auto HCT. 16 We therefore conducted a retrospective analysis to study the outcome of patients who relapse after auto/allo HCT versus auto/auto HCT.
Patients and Methods

Patients
There were 1679 patients who either received an upfront auto/auto (n=1186) or auto/allo HCT (n=569) for MM reported to the CIBMTR between 2000 and 2010 in North America. We excluded patients who had relapsed between the 2 transplants. Patients who received their 2 nd transplant later than 6 months after 1 st transplant were also excluded. After exclusion, there were 558 patients in auto/auto group and 264 patients in auto/allo group remained for further analysis. We studied patients who either relapsed or progressed and the term "relapse" in this analysis will represent both relapsed and progressive disease categories. Detailed eligibility criteria are shown in Figure 1 and Supplemental table 2 . For allo HCT, we selected only peripheral blood stem cell source. High risk myeloma was defined as del17p, t(4;14), t(14;16), hypodiploidy (<45 chromosomes excluding -Y) or chromosome 1 p and 1q abnormalities. 19
Statistical analysis
We compared post-relapse OS between auto/allo HCT cohort versus the auto/auto HCT cohort.
Our secondary objective was to identify factors associated with long term survival after tandem transplantation (auto/allo or auto/auto).
We tested differences between the patient groups using the chi-square test and Kruskal-Wallis test for categorical and continuous variables, respectively. For univariate analyses, survival probabilities were calculated by using the Kaplan-Meier estimator with the variance estimated by Greenwood's formula. 
Post
Patient Characteristics
The majority of patients were male (58 % auto/allo and 60% in auto/auto group). The median age was lower in auto/allo patients at 51 years and 56 years in auto/auto group. The majority of patients had a KPS of ≥90% (71% and 60% for auto/allo and auto/auto, respectively). Five percent of patients in both groups were high-risk by cytogenetics, though data were missing in 35% of patients.
Transplant-related characteristics
1 st transplant-related characteristics 73% of auto/allo patients and 90% of auto/auto patients received 1-2 lines of therapy before their 1 st transplant indicating that the cohorts in this study were less heavily pretreated. The use of novel agents at induction was higher in auto/auto group (73%) versus the auto/allo group (58%) (p=<0.001). The incidence of partial response or higher (≥PR) before 1 st HCT was also higher in auto/auto group (88%) than auto/allo group (82%) (p < 0.001). The majority of patients received melphalan at 200 mg/m 2 at first transplant in both groups. The median time from diagnosis to 1 st HCT was 8 months in auto/allo group and 7 months in auto/auto patients again reflecting the upfront use of HCT in these cohorts.
2nd transplant-related characteristics
The complete response (CR) rate before the 2 nd HCT was 19% and 14% in auto/allo and auto/auto group, respectively. The 2 nd HCT was done within 3 months of the 1 st HCT in 39% of patients in auto/allo group and 29% in auto/auto group.
In the auto/allo group, the majority of the patients (96%) received HLA-matched donor grafts and matched unrelated donors represented only 4% of the group. Almost all patients who received auto/allo HCT were conditioned with myeloabalative regimen (table 1) . Cyclosporine and mycophenolate mofetil were the most commonly used drugs for graft vs. host disease (GVHD) prophylaxis in 65% of the auto/allo group.
There were 18 patients who received donor lymphocyte infusion (DLI) and only one patient received DLI as a planned therapy and remaining 17 patients received DLI for relapse after allogeneic transplant. The patients who received DLI didn't have superior OS compared to patients who didn't receive DLI ( Supplemental table 3 ).
Post 2 nd transplant outcomes
28.7 % of patients in the auto/auto group received some form of maintenance chemotherapy as opposed to 8.8 % in auto/allo group (p<0.001). In the auto/allo cohort, the incidence of grade II-IV acute GVHD (aGVHD) was 24 % and grade III-IV was 11%. 58% of patients developed chronic GVHD (cGVHD). The median follow up time from relapse was 102 months for auto/allo and 99 months for auto/auto group, respectively. High proportion of patients (46%) relapsed within 6 months after auto/allo HCT but only 26% of auto/auto patients relapsed in the same time frame. There were more relapse in auto/auto group (39%) than auto/allo patients (24%) 2 years after 2 nd HCT.
Post-relapse OS
In univariate analysis, the 6 year probability of survival in auto/allo group was 44% compared to 35% in auto/auto group (p=0.05). (Table 2) .
After a median follow up of 102 months, 101 patients in the auto/allo group had died, 70 patients (69 %) were due to myeloma and 4 patients (4%) from GVHD ( On multivariate analysis, a pattern of differential time-dependent risk of mortality was observed.
Both cohorts had a similar risk of death in the 1st year after relapse (HR of 0.72; p=0.12).
However, beyond 12 months post-relapse, patients in the auto/allo group had a superior OS compared with auto/auto cohort (HR for death in auto-auto=1.55; p=0.005) ( Table-4 ).Significant co-variates associated with superior post-relapse survival included enrollment in a clinical trial for HCT (HR for death in patients not on trial= 1.39; p=0.005), male sex (HR for death in female patients= 1.27; p=0.03) and the use of novel agent/s in pre-transplant chemotherapy (HR of death for non-novel agent therapy=1.43; p=0.0023) ( Table 4 ).
When OS was adjusted using statistically significant variables from multivariate analysis (i. e. differential time effect of 12 months, sex, clinical trial enrollment and novel agent use), the probability of OS was higher for auto/allo patients (45%) than auto/auto patients (35%) at 6-year after relapse (p=0.035) ( Supplemental table 5 ). Figure 2 represents graphic presentation of adjusted post-relapse survival.
Discussion
In this large retrospective registry study analyzing long term post-relapse survival among MM patients who underwent auto/auto versus auto/allo HCT, we found that patients who und erwent auto/allo HCT had a long term post relapse survival advantage beginning after 12 months postrelapse. Similar findings which were initially reported by Gahrton et al. 16 in allogeneic HCT with matched sibling donors are confirmed in our data using a larger real world population of related and unrelated grafts.
Clinical trial enrollment was also found to have positive effect on OS, possibly due to better patient selection and closer monitoring. Novel agent therapy at induction also decreased risk of death compared to standard chemo therapy. In multivariate analysis of OS, male sex was found to have reduced risk of death but age was not found to have significant impact on survival. The median age for auot/allo group is younger (51 vs. 56) compared to auto/auto group. It is probably due to selection bias to choose younger patients by the treating physicians to proceed with auto/allo HCT. The median age for auto/allo group is also younger compared to auto/auto group in largest randomized auto vs. allo HCT trial reported by Krishnan et al. 12 CR rate after first HCT were lower in our study compared to auto vs. allo HCT trial reported by Krishnan et al 12 which may indicate a bias toward doing a 2 nd HCT among patients with suboptimal CR rates to 1 st HCT.Benefit for allogeneic HCT generally takes time to be observed, as seen in the European Blood and Marrow Transplant study 15, 16 which showed no significant difference in the groups at three years but follow up at five and eight years demonstrated the advantage of allogeneic HCT. Our analysis, with a median follow up time of 102 months (8.5 years) after relapse confirms a statistically significant adjusted survival benefit for the allogeneic cohort versus tandem autologous HCT (p=0.035) (Supplemental Table5).
Almost half the relapses (46%) in the auto/allo group happened early i.e. within six months after the second HCT, versus one quarter of the relapses (26%) in the auto/auto group. This was in spite of the fact that 90% of patients in both group achieved ≥PR or better before 2 nd HCT. The difference is likely secondary to the reduced intensity conditioning (RIC) for allo HCT which relies on donor lymphocyte effect (that may take up to a year to fully develop) to prevent relapses vs. myeloablative conditioning (73% of patients received 200mg/m2 of melphalan) in the auto/auto group. Selection bias by treating physicians to enroll MM patients with more aggressive/higher risk disease could have been a factor contributing to higher relapses in auto/allo patients. Similar early relapses post-allogeneic HSCT were also noted in other studies. 12, 20, 21 In addition, a higher usage of post-transplant maintenance therapy in the auto/auto patients (28.7% vs. 8.8%) could have played a role in delaying early relapse post auto transplant vs. post allo transplant. Lower usage of maintenance therapy especially after auto HCT reflects the era of our study (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) when the maintenance therapy was not commonly used.
The Incidence of cGVHD seems to be higher in our trial (58%) compared to findings from others 20,22 but we were unable to evaluate the effect of cGVHD on post relapse survival as cGVHD is a time-dependent covariate starting at the time of transplant and our study starts from time of relapse. We do note that 24% of our patients had history of grade II-IV aGVHD;
presumably, aGVHD predated the relapse after allogeneic HCT as the median time to relapse was 9 months.
Our study focused on patients who received their allogeneic HCT as a tandem approach after a prior auto HCT within six months after first transplant. We excluded patients undergoing allo HCT for relapse after an auto HCT. The median interval between diagnosis and first HCT was seven months in the auto/allo group. The overwhelming majority of allo HCT donors in our study were HLA-matched siblings (96%). The study population of auto/allo HCT matches a better risk we hypothesize that post-alloHCT immune manipulation can further augment GVM immune effects and should be studied in clinical trials. Finally, the early relapse after allo HCT in our study also demonstrates that immunologic effect against MM may take time to occur and early immune manipulation after transplant may be a logical design in future clinical trials. 
